Clinical Trial

Lurbinectedin in FET-Fused Tumors

Study acronym: LiFFT
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to find out if a drug called lurbinectedin (the "study drug") is safe and effective at treating people with recurrent or relapsed solid tumors, including Ewing sarcoma.
Protocol Amendment History 18 amendments
This ClinicalTrials.gov record has been amended 18 times since 2023-06-15; most recent amendment 2026-03-26.
Status change: Not Yet Recruiting → Recruiting 2023-07-27
Trial Details
NCT Number NCT05918640
Lead Sponsor Children's Hospital of Philadelphia
Collaborators: Jazz Pharmaceuticals, Stand Up To Cancer
Conditions Ewing Sarcoma, Desmoplastic Small Round Cell Tumor, Pediatric Cancer, Undifferentiated Sarcoma
Enrollment 63 participants
Start Date 2023-07-27
Primary Completion 2027-07-30 (estimated)
Study Completion 2028-07-30 (estimated)
Updated on ClinicalTrials.gov 2026-03-31